Newman Dignan & Sheerar, Inc. Clearside Biomedical, Inc. Transaction History
Newman Dignan & Sheerar, Inc.
- $386 Million
- Q4 2024
A detailed history of Newman Dignan & Sheerar, Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 30,123 shares of CLSD stock, worth $30,725. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,123
Previous 28,023
7.49%
Holding current value
$30,725
Previous $35,000
14.29%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11.6MCall Options Held
24KPut Options Held
12.1K-
Vanguard Group Inc Valley Forge, PA2.81MShares$2.86 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.24 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.97 Million0.03% of portfolio
-
Black Rock Inc. New York, NY798KShares$814,0990.0% of portfolio
-
Geode Capital Management, LLC Boston, MA764KShares$779,3390.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $61.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...